Soren Weis Dahl Email & Phone Number

Waltham, MA, US

Supporting Axcynsis' development of its IND-stage ADC therapeutics employing Axcynsis' proprietary, first-in-class AxcynDOT payload

Consultancy providing strategy and business development and investment advisory services to life science investors and companies. Search and evaluation of late preclinical and early clinical opportunities.

Malmö, Skåne County, SE

Director on the board with special insights into orphan drug development and US opportunities

Led Columbia University spinout DeckTherapeutics on its mission to pioneer neuroprotection using intravenous omega-3 diglyceride therapeutics. Secured funding from two institutional investors and a non-dilutive grant from the Bill & Melinda Gates Foundation. Oversaw the progression of the lead asset to late preclinical stage.

Tromsø, Troms, NO

Led strategy, and business and organizational development to drive evolution to clinical-stage, orphan drug company and investor exit in transaction with US orphan drug specialist Rallybio (www.rallybio.com). Established and managed vital relationships with CMC, development, and commercial partners. Drove strategy to obtain dual FDA/EMA compliant product.

Tromsø, Troms, NO

Drove regulatory and partnering strategy development and implementation across North America and Europe. Steered subcontracting of drug manufacturing. Developed organization to a near-clinical stage company. Led investor presentations and interactions.

Tromsø, Troms, NO

Coordinator of the EU FP-7 project PROFNAIT (www.profnait.eu). The 11 organizations in the Northern European consortium seek to develop a new prophylactic treatment of the rare disease fetal/neonatal alloimmune thrombocytopenia (FNAIT).

Established and led US drug and business development activities. Built and managed key alliances, including with medical advisors, plasma suppliers, drug manufacturer, consultants, investors, regulators and other stakeholders based in North America.

Hørsholm, DK

Consulted to diverse companies on biotech strategy and business development, scientific and commercial assessments/due diligence, valuations and deal structuring. Contributed directly to business transformation and investment decisions. Authored successful orphan drug applications to EMA and FDA.

Glostrup, DK

Managed a large, international reagents development and pre-marketing project. Aligned development processes and quality standards across two countries, and achieved full integration on automated platform. Delivered product line launch on time and on budget. Dako is now Agilent Technologies.

Ballerup, DK, DK

Drove balanced scorecard and user requirement specifications for PV database.

Ballerup, DK, DK

Led implementation of formal project management in Discovery organization, steering committee facilitation, and optimization of process for scientific assessment of in-licensing opportunities.

DK

Full-time project management and commercialization of drug discovery projects. Represented company in commercial discussions with AstraZeneca, Becton Dickinson, Schering, and more.

Performed gene cloning and engineering and protein expression, purification, and characterization. Drove external collaborations with academic groups that led the first X-ray structures of a 160,000 kDa dipeptidyl peptidase.

Mba, Business Administration And Management, General

M.Sc. Ph.D., Molecular Biology And Recombinant Protein Chemistry